<div id="readability-page-1"><div><p>Government bond yields are climbing, inflation pressures are sticky, and energy and geopolitics are keeping markets on edge. In this kind of rate driven market, investors often look for stocks that can hold up when conditions are choppy. That is where the Low-Risk Leaders screener comes in. It focuses on companies with stronger balance sheets and lower model risk scores. It is designed to help you build a sturdier core in your portfolio without walking away from return potential. In this article, you will see 3 stocks from this screener that fit that low risk, resilient profile.</p> <h2>Citizens Financial Group (CFG)</h2> <p><strong>Overview:</strong> Citizens Financial Group is a US bank that provides a full range of consumer and commercial banking services, from everyday deposits, mortgages, cards, and wealth management to corporate lending, capital markets advice, and risk management solutions for businesses and institutions.</p> <p><strong>Operations:</strong> Citizens generates about US$6.0b of revenue from Consumer Banking and US$2.5b from Commercial Banking, with total revenue of roughly US$7.9b coming from customers in the United States.</p> <p><strong>Market Cap:</strong> US$25.9b</p> <p>Citizens Financial Group stands out in a low risk screen because it combines a focus on credit quality and capital strength with clear levers for earnings and efficiency. The bank is leaning into AI and automation through its Reimagine the Bank program, targeting hundreds of millions of dollars in pretax efficiencies, while its fast growing private bank already contributes around 10% of pretax income on more than US$16b of deposits. The P/E currently sits close to peers. The key tension for you to weigh is whether commercial real estate exposure and regional concentration could offset these strengths as the cycle evolves.</p> <p>Citizens’ push into AI driven efficiency and a growing private bank could be masking a much bigger shift in earnings quality, so weigh that story against the full valuation picture with the DCF valuation analysis for Citizens Financial Group.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/4e00a58a-add4-487b-bb12-144763c93888/chart/dcf/query-ZGF0ZT0yMDI2LTA1LTE2"/><figcaption>CFG Discounted Cash Flow as at May 2026</figcaption></figure> <h2>United Therapeutics (UTHR)</h2> <p><strong>Overview:</strong> United Therapeutics is a biotechnology company that develops and sells therapies for serious cardiopulmonary conditions such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. It is also working on next generation organ and tissue technologies, including xenotransplantation and regenerative medicine platforms.</p> <p><strong>Operations:</strong> United Therapeutics generates about US$3.2b of revenue from pharmaceuticals, with roughly US$3.0b from customers in the United States and about US$138m from the rest of the world.</p> <p><strong>Market Cap:</strong> US$24.4b</p> <p>United Therapeutics sits at the intersection of high margin specialty drugs and a long term focus on organ and tissue technologies, with a Tyvaso franchise supported by IPF data and a pipeline that extends from ralinepag to gene edited organs such as UHeart. A solid balance sheet and sizeable buyback capacity give it room to continue funding R&amp;D while returning cash to shareholders. The company still faces risks, including concentrated exposure to pulmonary diseases, substantial trial and R&amp;D spending, and potential drug pricing pressure if key programs face setbacks. For investors assessing lower risk leaders, a key consideration is how much importance to place on the emerging organ platform relative to the established pulmonary business.</p> <p>United Therapeutics’ organ technology story could be quietly reshaping how the pulmonary drug business is valued, yet most focus still sits on existing therapies. Get the full context in the analyst forecasts for United Therapeutics to see what might be missing.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2"/><figcaption>NasdaqGS:UTHR Earnings &amp; Revenue Growth as at May 2026</figcaption></figure> <h2>Palantir Technologies (PLTR)</h2> <p><strong>Overview:</strong> Palantir Technologies builds software platforms that help governments and companies pull together huge amounts of data, spot patterns, and support real time decisions in areas like defense, security, and operations.</p> <p><strong>Operations:</strong> Palantir generates about US$2.8b from Government customers and US$2.5b from Commercial customers, with roughly US$4.0b coming from the United States, US$467.8m from the United Kingdom, and US$782.7m from the rest of the world.</p> <p><strong>Market Cap:</strong> US$320.6b</p> <p>Palantir sits at the center of government and enterprise AI adoption, with high margin software that is already embedded in critical US defense programs and large commercial rollouts through partners such as SAP, Accenture, Stellantis, and LG CNS. Earnings and revenue are both forecast to grow more than 29% a year, and profitability is currently strong. However, the stock trades on a very rich P/E, so even minor disappointments or rising competition in AI could trigger sharp swings. In addition, regulatory scrutiny around data use and recent insider selling create a complex risk reward setup that many investors are still only partly factoring in.</p> <p>Palantir’s AI story and rich P/E suggest the market may be pricing the obvious rather than the next chapter. Consider pressure testing that growth versus valuation trade off with the analyst forecasts for Palantir Technologies.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f8e4a674-51cb-4764-b739-5058e13a50ef/chart/earnings-and-revenue-growth/query-ZGF0ZT0yMDI2LTA1LTE2"/><figcaption>NasdaqGS:PLTR Earnings &amp; Revenue Growth as at May 2026</figcaption></figure> <p>The three stocks you have just seen are only a small sample of what this idea turns up, with the full Low-Risk Leaders screen surfacing 63 more companies in the Low-Risk Leaders screener that each have their own case for resilient balance sheets and lower model risk. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the opportunities that best fit your portfolio.</p> <h2>Take Control of Your Investment Journey</h2> <p> If United Therapeutics or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.             Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.             Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.             By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.         </p> <h2>Seeking Fresh Alternatives Before Others Catch On?</h2> <p>Markets move fast and the best setups rarely stay quiet for long. To spot fresh momentum, potential breakouts, and stocks still flying under the radar for now, consider taking action while conditions remain favorable.</p> <ul> <li>Track sturdy earners with room to grow by scanning a curated list of solid balance sheet and fundamentals (45 results) that can help you avoid fragile stories before the cracks show.</li> <li>Follow early strength in metal producers through a focused group of 34 elite gold producer stocks that may respond when sentiment shifts toward hard assets.</li> <li>Monitor under-the-radar operators using a targeted pool of 22 high quality undiscovered gems before the broader market evaluates their cash flow and balance sheet quality.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

UTHR

PLTR

PLTU

<p>In a volatile market, investors are turning to low-risk stocks. This article highlights three companies: Citizens Financial Group, a US bank focusing on AI and efficiency; United Therapeutics, a biotech firm developing therapies for pulmonary conditions; and Palantir Technologies, which provides data software for defense and commercial sectors. Each company shows strong revenue potential but faces unique risks, including market competition and regulatory scrutiny. Investors should weigh these factors against growth forecasts and valuations.</p>

- Government bond yields are rising, impacting market conditions, leading investors to seek resilient stocks, highlighted by the Low-Risk Leaders screener.  
- The article discusses three companies: Citizens Financial Group, United Therapeutics, and Palantir Technologies, each noted for their strong financial health and growth potential despite underlying risks.  
- The Low-Risk Leaders screen reveals additional potential investment opportunities, emphasizing the importance of thorough investment analysis and monitoring market dynamics.

3 Low Risk Leaders Powering AI, Pulmonary Drugs And Defense